VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q1 2024
Holdings as of Mar 31, 2024, filed May 15, 2024. Long positions only; changes compare share counts with Q4 2023.
- Positions
- 38
- +2 vs. Q4 2023
- Portfolio value
- $2.10B
- +$644.1M (+44.2%) vs. Q4 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| APGEApogee Therapeutics, Inc. | COM | 8,493,321 | $564.4M | 26.8% | 00.0% | Unchanged | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 4,400,000 | $140.2M | 6.7% | +975,969+28.5% | Added | History |
| OCULOcular Therapeutix, Inc | COM | 12,762,462 | $116.1M | 5.5% | +4,986,702+64.1% | Added | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 2,171,782 | $82.4M | 3.9% | −200,932−8.5% | Reduced | History |
| MRUSMerus N.V. | COM | 1,790,214 | $80.6M | 3.8% | −358,000−16.7% | Reduced | History |
| PHVSPharvaris N.V. | COM | 3,395,606 | $78.5M | 3.7% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 6,249,731 | $74.1M | 3.5% | +2,157,000+52.7% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 4,026,331 | $70.8M | 3.4% | +1,071,429+36.3% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 3,882,671 | $68.0M | 3.2% | +480.0% | Added | History |
| DNTHDianthus Therapeutics, Inc. | COM | 2,094,373 | $62.8M | 3.0% | +1,166,667+125.8% | Added | History |
| DYNDyne Therapeutics, Inc. | COM | 2,173,913 | $61.7M | 2.9% | 00.0% | Unchanged | History |
| APLTApplied Therapeutics, Inc. | COM | 9,075,000 | $61.7M | 2.9% | +2,825,000+45.2% | Added | History |
| ORICOric Pharmaceuticals, Inc. | COM | 4,394,527 | $60.4M | 2.9% | +1,966,142+81.0% | Added | History |
| ATXSAstria Therapeutics, Inc. | COM | 3,608,645 | $50.8M | 2.4% | +382,839+11.9% | Added | History |
| MRSNMersana Therapeutics, Inc. | COM | 11,328,000 | $50.7M | 2.4% | 00.0% | Unchanged | History |
| ENGNenGene Therapeutics Inc. | COM | 2,565,841 | $43.5M | 2.1% | +2,565,841 | New | History |
| PRAXPraxis Precision Medicines, Inc. | COM NEW | 706,126 | $43.1M | 2.0% | +352,500+99.7% | Added | History |
| HLVXHilleVax, Inc. | COM | 2,075,000 | $34.5M | 1.6% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 5,129,167 | $34.5M | 1.6% | +445,000+9.5% | Added | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 1,818,182 | $33.2M | 1.6% | +1,818,182 | New | History |
| CABACabaletta Bio, Inc. | COM | 1,563,952 | $26.7M | 1.3% | −1,000,000−39.0% | Reduced | History |
| ARVNArvinas, Inc. | COM | 627,788 | $25.9M | 1.2% | 00.0% | Unchanged | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 9,000,000 | $25.8M | 1.2% | −1,412,872−13.6% | Reduced | History |
| AQSTAquestive Therapeutics, Inc. | COM | 5,555,555 | $23.7M | 1.1% | +5,555,555 | New | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 3,410,058 | $22.4M | 1.1% | −1,087,059−24.2% | Reduced | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 1,556,419 | $22.0M | 1.0% | +1,041,664+202.4% | AddedConverted for a 1-for-10 split | History |
| CELCCelcuity Inc. | COM | 970,000 | $21.0M | 1.0% | −915,538−48.6% | Reduced | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,345,780 | $19.2M | 0.9% | +347,210+34.8% | Added | History |
| IMTXImmatics N.V. | SHS | 1,750,000 | $18.4M | 0.9% | +1,750,000 | New | History |
| LYRALyra Therapeutics, Inc. | COM | 2,576,093 | $16.0M | 0.8% | +5000.0% | Added | History |
| CGONCG Oncology, Inc. | COM | 350,000 | $15.4M | 0.7% | +350,000 | New | History |
| IPSCCentury Therapeutics, Inc. | COM | 3,405,133 | $14.2M | 0.7% | +3,405,133 | New | History |
| TRVITrevi Therapeutics, Inc. | COM | 3,422,675 | $11.8M | 0.6% | +2780.0% | Added | History |
| TNYATenaya Therapeutics, Inc. | COM | 1,555,556 | $8.14M | 0.4% | +1,555,556 | New | History |
| MLYSMineralys Therapeutics, Inc. | COM | 555,554 | $7.17M | 0.3% | +555,554 | New | History |
| SLRNACELYRIN, Inc. | COM | 937,113 | $6.33M | 0.3% | 00.0% | Unchanged | History |
| EYPTEyePoint, Inc. | COM NEW | 250,000 | $5.17M | 0.2% | 00.0% | Unchanged | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 77,042 | $872.1K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q4 2023 (6)
Positions held at the end of Q4 2023 that are gone from this filing.
| Security | Class | Shares in Q4 2023 | Value in Q4 2023 | % of portfolio in Q4 2023 | History |
|---|---|---|---|---|---|
| RYZBRayzeBio, Inc. | COM | 4,030,471 | $250.6M | 17.2% | History |
| AMAMAmbrx Biopharma, Inc. | COM | 2,070,000 | $29.5M | 2.0% | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 495,983 | $22.8M | 1.6% | History |
| SVRASavara Inc | COM | 3,500,000 | $16.4M | 1.1% | History |
| GHRSGH Research PLC | ORDINARY SHARES | 1,318,327 | $7.65M | 0.5% | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 925,048 | $1.54M | 0.1% | History |